ESMO26: KEYNOTE-C93 backs chemo-free Keytruda in dMMR endometrial cancer
Phase III results support chemotherapy-free first-line Keytruda in dMMR but leave the most clinically relevant comparison untested.
Phase III results support chemotherapy-free first-line Keytruda in dMMR but leave the most clinically relevant comparison untested.